Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Marksans Pharma Ltd (MARKSANS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524404 NSE: MARKSANS Pharmaceuticals & Drugs | Small Cap | Marksans Pharma Share Price
₹336.70 4.10 (1.23%)
As on 23-Sep'26 11:42
Marksans Pharma Ltd (MARKSANS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524404 NSE: MARKSANS Pharmaceuticals & Drugs | Small Cap | Marksans Pharma Share Price
₹336.70 4.10 (1.23%)
As on 23-Sep'26 11:42
Key Metrics
Valuation Multiples
Market Cap
₹15,072 Cr.
Current Price
₹336.7
52-Week Low / High
₹156 / 350
TTM EPS
₹11.4
TTM Sales
₹3,172 Cr.
Book Value per Share
₹70.2
P/E Ratio
29.17
Lower than its 5-year historical median
Industry PE
54.8
Price to Book (P/B)
4.74
Lower than its 5-year historical median
Price to Sales (P/S)
4.75
Lower than its 5-year historical median
EV/EBITDA
17.29
Lower than its 5-year historical median
Dividend Yield
0.27%
Profitability Efficiency
Return on Equity (ROE)
15.31%
Outperforms industry median
Return on Capital Employed (ROCE)
21.10%
Outperforms industry median
Return on Assets (ROA)
11.85%
Operating Profit Margin
20.4%
Net Profit Margin
14.23%
Gross Profit Margin
21.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
14.23%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
12.78%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
9.79%
Asset Quality
Promoter Holding
43.87%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹3,134 Cr.
Equity
₹45.3 Cr.
Face Value
₹1
All Time Low / High
₹0.70 / 358.50
Check Before You Invest
Quality
Very GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Marksans Pharma Ltd a good quality company?
Marksans Pharma Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Marksans Pharma Ltd performance compare with that of its Peers?
Revenue growth of Marksans Pharma Ltd vs industry peers?
Marksans Pharma Ltd revenue CAGR is 16.48%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Marksans Pharma Ltd?
Promoters hold 43.87% of the Marksans Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Marksans Pharma Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Marksans Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 3.4% | 4.9% | 12% | 11.4% | 23.5% | 19.9% | 14.3% | 14.8% | 18.8% | 25.9% | - |
| Value Creation Index ⓘ | -0.8 | -0.7 | -0.1 | -0.2 | 0.7 | 0.4 | 0.0 | 0.1 | 0.4 | 0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 216 | 295 | 424 | 433 | 600 | 658 | 655 | 853 | 1,174 | 1,341 | 1,343 |
| Sales YoY Gr. | - | 36.5% | 44% | 2.2% | 38.3% | 9.8% | -0.5% | 30.2% | 37.6% | 14.2% | - |
| Adj EPS ⓘ | 0.1 | 0.2 | 1 | 0.9 | 2.4 | 2.2 | 1.8 | 2.8 | 3.9 | 5.9 | 7.1 |
| YoY Gr. | - | 80% | 450% | -6.1% | 160.2% | -9.5% | -16.4% | 54.1% | 36.5% | 53.3% | - |
| BVPS (₹) ⓘ | 10.2 | 10.5 | 11.5 | 12.4 | 14.7 | 16.9 | 24.5 | 27 | 30.5 | 36.4 | 37.9 |
| Adj Net Profit ⓘ | 3.9 | 7.3 | 40.7 | 37.9 | 99.1 | 89.5 | 83.1 | 128 | 175 | 268 | 322 |
| Cash Flow from Ops. ⓘ | -13.6 | 15.6 | 19.8 | 108 | 107 | 56 | 51.7 | 34.1 | 31 | 211 | - |
| Debt/CF from Ops. ⓘ | -5.4 | 4.3 | 3.9 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 22.5% | 17.5% | 27% | 14.2% | ||||
| Adj EPS ⓘ | 57.3% | 19.5% | 47.7% | 53.3% | ||||
| BVPSⓘ | 15.1% | 20% | 14.1% | 19.2% | ||||
| Share Price | 21.5% | 37.1% | 47.7% | 96.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.9 | 1.7 | 9 | 7.8 | 17.9 | 12.9 | 8.8 | 11 | 13.4 | 17.6 | 19.1 |
| Op. Profit Mgn % ⓘ | 6.3 | 9.9 | 14.9 | 16.5 | 19.1 | 17.3 | 12.8 | 16.4 | 17.7 | 24.1 | 25 |
| Net Profit Mgn % ⓘ | 1.8 | 2.5 | 9.6 | 8.8 | 16.5 | 13.6 | 12.7 | 15 | 14.9 | 19.9 | 24 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 352 | 278 | 223 | 227 | 165 | 187 | 238 | 253 | 240 | 241 | 161 |
| Cash Conv. Cycle ⓘ | 260 | 208 | 160 | 157 | 105 | 121 | 146 | 143 | 133 | 138 | 121 |
Valuation of Marksans Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,951 |
| Operating Expenses ⓘ + | 734 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,090 | 2,350 |
| Operating Profit ⓘ | 33 | 78 | 132 | 192 | 340 | 259 | 339 | 459 | 533 | 601 |
| Operating Profit Margin (%) | 4.3% | 8.6% | 13.2% | 17.0% | 24.7% | 17.4% | 18.3% | 21.1% | 20.3% | 20.4% |
| Other Income ⓘ + | 19 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 66 | 83 |
| Interest ⓘ | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 24 |
| Depreciation ⓘ | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 99 |
| Profit Before Tax ⓘ | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 561 |
| Tax ⓘ | 4 | 14 | 24 | 36 | 64 | 61 | 72 | 109 | 121 | 140 |
| Profit After Tax | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 420 |
| PAT Margin (%) | 1.5% | 3.9% | 8.0% | 10.7% | 17.3% | 12.5% | 14.3% | 14.5% | 14.6% | 14.2% |
| Adjusted EPS (₹) | 0.2 | 0.8 | 1.9 | 2.9 | 5.8 | 4.5 | 5.9 | 6.9 | 8.4 | 9.2 |
| Dividend Payout Ratio (%) | 23.20% | 6.20% | 2.70% | 3.50% | 4.30% | 5.50% | 8.50% | 8.70% | 9.50% | 9.80% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 433 | 471 | 542 | 636 | 886 | 1,109 | 1,745 | 2,065 | 2,467 | 3,020 | |
| Debt + | 110 | 117 | 100 | 19 | 19 | 41 | 42 | 29 | 23 | 30 | |
| Minority Interest | 6 | 10 | 10 | 13 | 19 | 21 | 20 | 21 | 22 | 30 | |
| Trade Payables | 162 | 78 | 106 | 110 | 169 | 200 | 231 | 268 | 306 | 337 | |
| Others Liabilities ⓘ | 41 | 55 | 44 | 124 | 135 | 289 | 153 | 298 | 421 | 432 | |
| Total Liabilities ⓘ | 752 | 731 | 802 | 902 | 1,228 | 1,660 | 2,190 | 2,681 | 3,240 | 3,848 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,044 | |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 | 59 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 0 | |
| Inventories | 190 | 218 | 293 | 242 | 404 | 424 | 485 | 618 | 846 | 972 | |
| Trade Receivables | 248 | 177 | 177 | 243 | 272 | 395 | 417 | 453 | 540 | 645 | |
| Cash Equivalents | 25 | 40 | 34 | 94 | 212 | 349 | 715 | 674 | 704 | 990 | |
| Others Assets ⓘ | 22 | 16 | 29 | 20 | 18 | 60 | 77 | 124 | 140 | 139 | |
| Total Assets ⓘ | 752 | 731 | 802 | 902 | 1,228 | 1,660 | 2,190 | 2,681 | 3,240 | 3,848 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 14 | 50 | 27 | 233 | 179 | 99 | 237 | 230 | 207 | 458 |
| Cash Flow From Investing Activity ⓘ + | -21 | -39 | -13 | -60 | -45 | -84 | -259 | -141 | -49 | -248 |
| Cash Flow From Financing Activity ⓘ + | -3 | 3 | -21 | -114 | -15 | 80 | 198 | -69 | -65 | -71 |
| Net Cash Flow ⓘ | -10 | 15 | -7 | 60 | 118 | 94 | 176 | 21 | 93 | 139 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.59 | 7.92 | 15.88 | 20.49 | 31.33 | 18.72 | 18.59 | 16.53 | 16.89 | 15.31 |
| ROCE (%) | 4 | 10.6 | 18.51 | 25.57 | 39.76 | 23.82 | 22.89 | 22.4 | 22.5 | 21.1 |
| Asset Turnover Ratio | 1.04 | 1.23 | 1.3 | 1.33 | 1.31 | 1.07 | 1.06 | 0.94 | 0.93 | 0.86 |
| PAT to CFO Conversion(x) | 1.27 | 1.39 | 0.34 | 1.93 | 0.75 | 0.53 | 0.89 | 0.73 | 0.54 | 1.09 |
| Working Capital Days | ||||||||||
| Receivable Days | 110.60 | 84.90 | 64.50 | 67.60 | 67.60 | 78.60 | 72.60 | 69.40 | 66 | 71.20 |
| Inventory Days | 85.10 | 81.60 | 93.30 | 86.10 | 84.70 | 97.70 | 81.40 | 87.90 | 97.20 | 109.20 |
| Payable Days | 111.70 | 83.60 | 67.40 | 69.60 | 85.60 | 93.90 | 85.30 | 87.70 | 91.60 | 91.80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Marksans Pharma Ltd FAQs
The current trading price of Marksans Pharma on 23-Sep-2026 11:42 is ₹336.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Marksans Pharma stood at ₹15,072.2 Cr
The latest P/E ratio of Marksans Pharma as of 22-Sep-2026 is 46.85.
The latest P/B ratio of Marksans Pharma as of 22-Sep-2026 is 8.77.
The 52-week high of Marksans Pharma is ₹349.7 and the 52-week low is ₹156.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Marksans Pharma is ₹1,343 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Marksans Pharma Ltd is a good quality company.
The key valuation ratios of Marksans Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Marksans Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Marksans Pharma Ltd
Marksans Pharma is at the forefront of the pharmaceutical industry, distinguished by a customer-centric approach. Specializing in Over-the-Counter (OTC) and prescription drugs, the company has cultivated a strong presence in highly regulated markets. Leveraging robust Research and Development (R&D) capabilities and advanced manufacturing facilities both domestically and internationally, the company is among the top five Indian Companies in the United Kingdom. The company’s strategic emphasis on optimizing supply chain efficiencies has facilitated substantial business expansion across key global markets. The company’s high-quality and expansive portfolio has led to a growing foothold in the USA as well.
Headquartered in Mumbai, the company has built a robust global footprint, actively operating in over several countries worldwide. The company’s integrated business approach, supported by a talented workforce, positions it for sustained long-term growth with a focus on value creation. The company’s key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Pain Management, Cough and Cold, Digestives, CVS, CNS Oncology, Antidiabetic, and Antibiotics, among others.
At the core of its operations is an unwavering commitment to quality. Rigorous Quality Control (QC) and Quality Assurance (QA) processes have positioned it as a niche player in the pharmaceutical ecosystem. Adherence to Current Good Manufacturing Practices (cGMP) norms is integral to its operations. Continuous improvement initiatives across products, processes, and skills ensure its offerings evolve to meet changing client needs. The company’s world-class manufacturing facilities have garnered approval from esteemed institutions such as the US FDA, UK MHRA, Australian TGA, and other foreign health authorities.
Business area of the company
The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.
Formulations business product portfolio
- Tablets (plain, enteric-coated and film-coated)
- Hard capsules
- Soft gelatin capsules
- Oral liquids
- Ointments
Consumer Self-Care Products
- Pain Management - Arthritis
- Upper Respiratory - Cough & Cold and Allergy
- Digestive Health
- VMS (Vitamins Minerals and Supplements)
- Skin Care Products
Prescription - Rx Therapeutic Segments
- Cardiovascular System (CVS)
- Central Nervous System (CNS)
- Oncology
- Anti-Diabetics
- Anti-Biotic
Milestones
- 2001: Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.
- 2003: Spun off into a separate entity – Glenmark Laboratories Ltd.
- 2003: Changed its name to ‘Marksans Pharma Ltd’
- 2005: Acquired Nova Pharmaceuticals Australasia Pty Ltd
- 2007: Acquired Bell, Sons & Co. (Druggists) Ltd. UK
- 2008: Acquired Relonchem Ltd. UK
- 2009: Marksans Pharma establlished itself as a global player
- 2015: Acquired TimeCapLaboratories Inc. USA
- 2017: Increased focus on OTC segment in US market
- 2022: Acquired Access Healthcare Dubai
- 2023: Raised Rs 372.40 crore in equity via conversion of warrants issued to OrbiMed and Promoters.
- 2023: Acquired a manufacturing facility from Tevapharm India.
- 2024: Marksans crossed Rs 2,000 crore revenue.
- 2026: Incorporated two new wholly owned subsidiary companies by name Marksans Pharma (Europe) and Marksans (Canada) Inc.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
